Live
- Tesla's Humanoid Robot 'Optimus': What to Expect and Its Potential Impact
- CBDT extends deadline for filing Form 10A/10AB by taxpayers to June 30
- Senior Congress Leader Maridu Krishna Files Nomination as MLA Candidate in Nuzividu Constituency
- TN: Five district collectors questioned by ED in illegal sand mining case
- Patsamatla Dharmaraju files 4th set of nomination papers as Jana Sena candidate for Ungutur Assembly Constituency
- Cong accepted country's division on basis of religion: PM Modi
- TN Police targeting me in Rs 4 cr cash seizure case, says BJP leader Nainar Nagendran
- Former Zimbabwe cricketer Guy Whittall injured by leopard
- Fatal Fire Erupts In Hotel Near Patna Junction, Claims Six Lives
- Congress Challenges PM Modi's Allegations: Calls Out "Falsehoods" Amidst Electoral Rhetoric
GNH Imports Life-Saving Medicine to India
India’s most accredited pharmaceutical wholesaler, GNH India has successfully imported a life-saving medicine called Olaratumab (trade name Lartruvo) that is now available through official import channels.
• Leading Pharmaceutical wholesaler GNH imports life-saving ‘orphan drug’ status
• An Orphan drug is named so as it is not easily available globally
• This drug is used to fight solid tumors and soft tissue sarcomas
India: India’s most accredited pharmaceutical wholesaler, GNH India has successfully imported a life-saving medicine called Olaratumab (trade name Lartruvo) that is now available through official import channels.
It is a monoclonal antibody developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. The cost of each injection isapproximately Rs. 1,72,500.
Dr Piyush Gupta, Associate Director, GNH India commented, “GNH India has always believed that everyone should have access to proper healthcare and medicines, and we strive to deliver the same to the people irrespective of the global boundaries. In this effort we have aimed to import a rare orphan status drug called, ‘Olaratumab’ that is used to treat soft tissue sarcoma. It gives us tremendous pleasure to be the first Indian specialized wholesaler to provide this life-saving medicine in India and we look forward to many more opportunities”
This drug is classified ‘Orphan drug’as it is not available easily world-wide.In February 2015, the European Medicines Agency assigned Olaratumab ‘orphan drug’ status for the treatment of soft-tissue sarcoma. The European Commission granted a conditional marketing authorization, based on a Phase II study, valid throughout the European Union on 9 November 2016.
